Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

Nicolas Boissel, Françoise Huguet, Thibaut Leguay et al. Nov 03, 2025 pp. 643-643 10.1182/blood-2025-643

Abstract Rationale. Young adults with Philadelphia chromosome–negative (Ph-negative) B-cell acute lymphoblastic leukemia (B-ALL) have benefi...

Bi-allelic germline SH2B3 loss in pediatric B-ALL with cirrhosis and autoimmunity

Farah Malaeb, Muhammed Ameen, Murtada Alsultan et al. Nov 03, 2025 pp. 6847-6847 10.1182/blood-2025-6847

Abstract SH2B3 encodes LNK protein, a negative regulator of JAK-STAT and RTK signaling. Pathogenic loss-of-function bi-allelic germline vari...

Enhanced engraftment and immune recovery in thalassemia via optimized conditioning for TCRαβ⁺-depleted haploidentical transplants

Jianyun Liao, Lan He, Zhaoke Bu et al. Nov 03, 2025 pp. 2427-2427 10.1182/blood-2025-2427

Abstract Background TCRαβ⁺/CD19⁺-depleted haplo-HSCT (TDH) reduces the risk of graft-versus-host disease (GVHD) in thalassemia major (TM) pa...

A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.

Hongyong Zhang, Zhipeng Cheng, Yingying Wu et al. Nov 03, 2025 pp. 7130-7130 10.1182/blood-2025-7130

Abstract Objective: Mucosa-associated lymphoid tissue (MALT) lymphoma represents a distinct subtype among marginal zone lymphomas (MZL). The...

The efficacy and safety of luspatercept in patients with low-blasts myelodysplastic neoplasms in real world

Huijuan Jiang, Lijuan Li, Jia Song et al. Nov 03, 2025 pp. 7400-7400 10.1182/blood-2025-7400

Abstract Backgroud: Myelodysplastic neoplasms (MDS) are characterized by myelodysplasia and ineffective hematopoiesis leading to refractory...

Caramel: Dual-targeting (CD123/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed/Refractory Acute Myeloid Leukemia. preclinical Results.

Ines Zugasti, Vladimir Mulens-Arias, Lady Espinosa-Aroca et al. Nov 03, 2025 pp. 7624-7624 10.1182/blood-2025-7624

Abstract Introduction Relapsed or refractory acute myeloid leukemia (R/R AML) remains a major therapeutic challenge. The application of chim...

Targeted liver assessment and the role of biopsy prior to gene therapy and HSCT in transfusion-dependent β-thalassemia: Addressing an unmet need in the absence of standardized protocols

Vismay Deshani, Nandini Sadasivam, Farhan Ali Anjum et al. Nov 03, 2025 pp. 7840-7840 10.1182/blood-2025-7840

Abstract Introduction Liver assessment plays a pivotal role in pre-transplant work up in gene therapy and Hematopoietic Stem Cell Transplant...

Research on co-mutated genes in FLT3-ITD-positive acute myeloid leukemia

Li Wan, Yujiao Jia, Yan Li et al. Nov 03, 2025 pp. 7027-7027 10.1182/blood-2025-7027

Abstract Background: The FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem duplication) mutation is prevalent in 20%–30% of acute myeloid...

CD19-directed CAR T-cell therapy for B-cell lymphoid malignancies is safe and effective in people living with HIV (PWH) – a matched cohort analysis by the center for international blood and marrow transplant research (CIBMTR) and the AIDS malignancy consortium (AMC)

Stefan Barta, Ariela Noy, Kwang Woo Ahn et al. Nov 03, 2025 pp. 955-955 10.1182/blood-2025-955

Abstract Background: Despite a decreasing incidence, NHL remains the leading cause of cancer-attributable deaths in PWH (Horner MJ, et al. C...

GVHD-free/relapse-free survival in severe aplastic anemia: Outcomes following allogeneic hematopoietic cell transplantation: King hussein cancer center experience

Mayada Abu Shanap, Iyad Sultan, Abeer Natsheh et al. Nov 03, 2025 pp. 2414-2414 10.1182/blood-2025-2414

Abstract Introduction: Severe Aplastic Anemia (SAA) is a life-threatening hematopoietic stem cell disorder; Allogeneic hematopoietic stem ce...

Retrospective analysis of 30mg/kg ATLG in preventing GVHD after haploidentical hematopoietic stem cell transplantation

Sanfang Tu, Minhong Huang, Chaoyang Song et al. Nov 03, 2025 pp. 7754-7754 10.1182/blood-2025-7754

Abstract Background: Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has emerged as a critical treatment option for pati...

Complement-induced procoagulant platelets in patients with antiphospholipid antibodies

Paresh Kulkarni, Maierdan Palihati, Anne Hubben et al. Nov 03, 2025 pp. 416-416 10.1182/blood-2025-416

Abstract Introduction Antiphospholipid syndrome (APS), an autoimmune disease characterized by persistent circulating antiphospholipid antibo...

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

Mahmoud Gaballa, Lei Feng, Aimaz Afrough et al. Nov 03, 2025 pp. 824-824 10.1182/blood-2025-824

Abstract Background Patients (pts) with multiple myeloma and CNS involvement (CNS MM) have poor outcomes, and we recently showed that CAR-T...

Impact of prolonged hospitalization on outcomes in acute leukemia: A national inpatient sample analysis

Ashish Sharma, Harendra Kumar, Angad Tiwari et al. Nov 03, 2025 pp. 6840-6840 10.1182/blood-2025-6840

Abstract Background: Acute leukemia (AL), which includes both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), often req...

Pre-treatment immune profiling by flow cytometry and single-cell transcriptomics identifies distinct features in B and T cells in rituximab responders and non-responders

Alicia Au, Michelle MH Tan, Akhil Khera et al. Nov 03, 2025 pp. 734-734 10.1182/blood-2025-734

Abstract Introduction Immune thrombocytopenia (ITP) is a heterogeneous autoimmune disorder defined by low platelet counts (<100×10⁹/L...

Use of emicizumab in patients with acquired hemophilia A: An interim safety analysis of a large-scale post‑marketing surveillance study

Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa et al. Nov 03, 2025 pp. 4854-4854 10.1182/blood-2025-4854

Abstract Background: Acquired hemophilia A (AHA) is a rare autoimmune disorder in which autoantibodies neutralize coagulation factor VIII (F...

Sight: Sickle cell identification from general hematological testing, a machine learning approach for rapid screening in emergency medicine

Jedrzej Konarkowski, Jonathan Wade, Vivien Sheehan Nov 03, 2025 pp. 1177-1177 10.1182/blood-2025-1177

Abstract Background: Rapid and accurate identification of sickle cell disease (SCD) is crucial in emergency medicine, with the chronic compl...

Efficacy of tocilizumab prophylaxis in preventing cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome: A systematic review and meta-analysis

Moazzam Shahzad, Hafiz Muhammad Hannan Javed, Hafsa Shahid et al. Nov 03, 2025 pp. 7602-7602 10.1182/blood-2025-7602

Abstract Introduction: Chimeric antigen receptor T cell therapy (CAR-T) and bispecific antibodies have revolutionized th...

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

Romain Guieze, Annamaria Frustaci, Chan Cheah et al. Nov 03, 2025 pp. 3584-3584 10.1182/blood-2025-3584

Abstract Introduction: BGB-16673 is an orally available protein degrader that blocks BTK signaling by tagging BTK for degradation through the...

Characterization of the human erythromyeloblastic islands (EMBIs)

Yasmin Elgammal, Athina Ntoumaziou, Laurel Romano et al. Nov 03, 2025 pp. 182-182 10.1182/blood-2025-182

Abstract The erythroblastic island (EBI) was first described in 1958, by Marcel Bessis, as a niche composed of a central macrophage (Μφ) sur...

Utility of diagnostic bone marrow examinations for cytopenias and impact on clinical management: A practice audit

Nina Castrogiovanni, Beau Bouliane, Candy Niu et al. Nov 03, 2025 pp. 6165-6165 10.1182/blood-2025-6165

Abstract Background: Bone marrow examination (BME) is frequently performed for unexplained cytopenias, with wide variations in clinical thre...

Title: Role of primary VTE prophylaxis in pediatric leukemia, lymphoma, and solid tumors: A systematic review and meta-analysis.

Qais Hamarsha, Ali Choaib, Muayad Azzam et al. Nov 03, 2025 pp. 3139-3139 10.1182/blood-2025-3139

Abstract Background/ introduction: Venous thromboembolism (VTE) is an increasingly recognized cause of morbidity in children, particularly am...

Safety and efficacy of implanted port use for CAR T-cells infusion in large B-cell lymphoma

Zachary Hunzeker, Anath Lionel, Xiaowen Sun et al. Nov 03, 2025 pp. 2713-2713 10.1182/blood-2025-2713

Abstract Background: Peripherally inserted central catheter (PICC) is the most commonly utilized central venous access for chimeric antigen...

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and reed-stenberg cells reveals escape from NK cell recognition and an unfolded protein response

Mikhail Roshal, Isabella Kong, Wikum Dinalankara et al. Nov 03, 2025 pp. 3538-3538 10.1182/blood-2025-3538

Abstract Classic Hodgkin lymphoma (cHL) is a B cell malignancy characterized by rare malignant Hodgkin and Reed-Sternberg (HRS) cells within...

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Mark Hamilton, Ajlan Al Zaki, Lei Feng et al. Nov 03, 2025 pp. 5485-5485 10.1182/blood-2025-5485

Abstract Introduction. Approximately 30% of patients with large B-cell lymphoma (LBCL) achieve a partial response (PR) after CAR T-cell ther...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page